Company news
Veru Inc. news in 2025
Veru Inc.'s news releases, calls and decks from 2025, newest first.
Annual Report for Fiscal Year Ending 09-30, 2025 (Form 10-K)
December 18, 2025
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
December 17, 2025
Veru to Report Fiscal Year 2025 Financial Results on December 17th
December 10, 2025
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
December 4, 2025
Veru to Present Two Abstracts at ObesityWeek 2025
October 31, 2025
Veru Announces Pricing of $25 Million Public Offering
October 30, 2025
Veru Announces Proposed Public Offering
October 29, 2025
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
September 23, 2025
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
August 12, 2025
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
August 11, 2025
Veru Announces Reverse Stock Split
August 6, 2025
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
August 5, 2025
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
July 22, 2025
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
June 24, 2025
Veru to Participate in the Virtual BTIG Obesity Health Forum
June 11, 2025
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
May 28, 2025
Veru Participates in a Virtual Investor KOL Connect Segment
May 8, 2025
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
May 8, 2025
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
May 1, 2025
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
April 16, 2025
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
March 31, 2025
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
February 12, 2025
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
February 5, 2025
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
January 26, 2025